News

Public · Published

Mirum Pharmaceuticals Q3 net product sales surge, outlook raised

Mirum Pharmaceuticals reported third-quarter net product sales of $185.72 mln and a net loss of $40.77 mln. It raised its full-year 2026 net product sales outlook to $715 mln–$720 mln. LIVMARLI sales grew 45% year over year, and Bile Acid Medicines sales rose 28%.

Published:

Updated:

What happened

Mirum Pharmaceuticals reported third-quarter net product sales of $185.72 mln and a net loss of $40.77 mln. It raised its full-year 2026 net product sales outlook to $715 mln–$720 mln. LIVMARLI sales grew 45% year over year, and Bile Acid Medicines sales rose 28%.

Confirmed

Global impact / market context

Growing product sales and a higher outlook point to stronger demand that could expand future revenue. But the quarterly loss alongside operating expenses of $245.47 mln shows costs remain substantial, so sales growth has not yet translated into a profit for investors to assess.

Analyst inference

The article reports a $153 median 12-month analyst price target, about 78.4% above Mirum’s November 2 closing price of $85.74, and an average buy rating. These are analyst views, not guarantees of future share performance.

Confirmed

What to watch

  1. Compare future sales reports with the raised full-year outlook, and assess whether growth across Mirum’s medicines continues strongly enough to support the company’s stated expectations. Analyst inference
  2. Review operating expenses and net losses in subsequent results: if costs keep rising faster than sales, additional product revenue may not improve the company’s financial results. Analyst inference
  3. The company attributed LIVMARLI growth to expansion into additional rare cholestatic liver diseases; it said Bile Acid Medicines sales rose with increased demand for CHOLBAM and CTEXLI. Confirmed

Evidence

  • Original source link unavailable